Aegerion Pharmaceuticals (NASDAQ:AEGR) CEO Marc Beer sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $87.79, for a total value of $3,511,600.00. Following the completion of the sale, the chief executive officer now directly owns 195,726 shares of the company’s stock, valued at approximately $17,182,786. The transaction was disclosed in a filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at FBR & Co. initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $105.00 price target on the stock. Eleven analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $89.46.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 86.00 on Thursday. Aegerion Pharmaceuticals has a 52-week low of $13.33 and a 52-week high of $101.00. The stock’s 50-day moving average is $86.71 and its 200-day moving average is $73.8. The company’s market cap is $2.491 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, October 29th. The company reported ($0.43) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.50) by $0.07. The company had revenue of $16.30 million for the quarter, compared to the consensus estimate of $13.07 million. The company’s quarterly revenue was up 1629900.0% on a year-over-year basis. Analysts expect that Aegerion Pharmaceuticals will post $-2.19 EPS for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.